The following data is part of a premarket notification filed by Valeant Pharmaceuticals with the FDA for Biafine.
Device ID | K173549 |
510k Number | K173549 |
Device Name: | BIAFINE |
Classification | Dressing, Wound, Drug |
Applicant | Valeant Pharmaceuticals 1400 North Goodman Street Rochester, NY 14609 |
Contact | Melissa Thomas |
Correspondent | Marci Halevi Valeant Pharmaceuticals 400 Somerset Corporate Boulevard Bridgewater, NJ 08807 |
Product Code | FRO |
CFR Regulation Number | 510(k) Premarket Notification [🔎] |
Decision | Substantially Equivalent (SESE) |
Type | Traditional |
3rd Party Reviewed | No |
Combination Product | Yes |
Date Received | 2017-11-16 |
Decision Date | 2018-08-13 |
Summary: | summary |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
BIAFINE 75392423 2270330 Live/Registered |
BAUSCH HEALTH IRELAND LIMITED 1997-11-19 |
BIAFINE 75392423 2270330 Live/Registered |
WENMAEKERS, Michel 1997-11-19 |
BIAFINE 74496392 1923213 Live/Registered |
BAUSCH HEALTH IRELAND LIMITED 1994-03-01 |
BIAFINE 74496392 1923213 Live/Registered |
WENMAEKERS, Michel 1994-03-01 |